Obexelimab

Obexelimab is an experimental drug developed to treat IgG4-related disease and lupus.It works as a "bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells."[1][2]This pharmacology-related article is a stub.You can help Wikipedia by expanding it.
Monoclonal antibodyTargetLegal statusCAS NumberDrugBankIgG4-related diseaseB cellsplasmablastsplasma cellspharmacology